EQS-News: CHEPLAPHARM closes financial year 2023 with record revenue and double-digit growth
- 59
EQS-News: Cheplapharm AG
/ Key word(s): Annual Results/Annual Report
CHEPLAPHARM CLOSES FINANCIAL YEAR 2023 WITH RECORD REVENUE AND DOUBLE-DIGIT GROWTH
The CHEPLAPHARM Group, a global leader in the acquisition of originator products from the research-based pharmaceutical industry, closed the financial year 2023 with a record revenue of € 1,498.4 million. The company, headquartered in Greifswald/Germany, is continuing its dynamic and profitable double-digit percentage growth track. In addition to the revenue record, the opening of the affiliates in Japan and Switzerland are important milestones in the transformation to an international group of companies. The largest transaction in the company's history, the acquisition of the Zyprexa® portfolio from Eli Lilly for a purchase price of around € 1.3 billion, rounds off the successful financial year 2023.
The annual financial statements for the financial year 2023 published today show a year-over-year increase in revenue of +17% to € 1,498.4 million (FY2022: € 1,279.5 million). EBITDA totalled € 780.5 million in the reporting period, an increase of +14% compared to the financial year 2022 (FY2020: € 685.7 million). At 52%, the EBITDA margin remained at a high and industry-leading level in 2023. CHEPLAPHARM is thus continuing its dynamic and profitable growth track over the last years in 2023 as well and significantly exceeding the targets it has set itself. "We look back on an extremely successful year 2023 and continued to grow profitably in a challenging market environment. In addition to this dynamic growth, we have also consistently driven forward our transformation into an international group of companies. Within just a few months, we have established two fully operational affiliates in Japan and Switzerland with over 30 new colleagues," says Edeltraud Lafer, CEO of CHEPLAPHARM, summarising the positive results. "In the financial year 2023, we were also very successful on the capital market and raised more than one billion euros with two bonds," adds Dr Kia Parssanedjad, CFO of CHEPLAPHARM. "This enabled us to finance the acquisition of the Zyprexa® portfolio and further strengthen our liquidity position. The two successful placements demonstrate investors' great confidence in the strength and resilience of our business model and give us the flexibility to further invest in attractive branded medicines in the current financial year 2024 and thus continue our growth track." As a profitable and steadily growing company, CHEPLAPHARM is an attractive employer. The number of employees rose by 131 to 666 at the end of the year, an increase of 24% compared to the previous year. The majority of the new colleagues started work at the headquarters in Greifswald. This means that CHEPLAPHARM remains one of the most important employers in the region.
About CHEPLAPHARM
26.04.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | Cheplapharm AG |
Ziegelhof 24 | |
17489 Greifswald | |
Germany | |
Phone: | 03834 3914 O |
E-mail: | [email protected] |
Internet: | www.cheplapharm.com |
ISIN: | DE000CHP2222 |
WKN: | CHP222 |
EQS News ID: | 1890701 |
Notierung vorgesehen |
End of News | EQS News Service |
|
1890701 26.04.2024 CET/CEST
EQS Group est un leader mondial de solutions digitales pour la communication financière et corporate et la compliance. Plus de 8 000 sociétés dans le monde font confiance aux services d’EQS Group pour s’adresser de façon efficace et sécurisée à une audience nationale et internationale de partenaires et pour se conformer aux directives et obligations réglementaires.
- DBV Technologies annonce son intention de modifier le ratio d'ADS
- Metalliance, filiale de GAUSSIN SA, a été placée en redressement judiciaire
- KPS CAPITAL PARTNERS VA ACQUÉRIR INNOMOTICS AUPRÈS DE SIEMENS AG
- mdf commerce annonce la réalisation de l’acquisition par KKR
- ADOMOS ANNONCE AVOIR SAISI LE TRIBUNAL DE COMMERCE DE PARIS EN VUE DE L'OUVERTURE D'UNE PROCÉDURE COLLECTIVE
- Société Générale : Descriptif du programme de rachat d’actions sous réserve de l’autorisation de l'Assemblée générale mixte du 22 mai 2024